AGP Executive Report
Last update: 5 hours agoClinical Trial Breakthrough: A randomized trial found a single 10 mg oral hydrocortisone dose improved attention and verbal learning within hours in virally suppressed women with HIV, with daily dosing over four weeks linked to better delayed memory recall. Behavioral Health Funding: HHS/SAMHSA awarded $77M in new grants for substance use prevention, community mental health, suicide prevention, and crisis services. Long COVID Update: In the RECOVER-VITAL trial, extending Paxlovid to up to 25 days showed no clinical benefit for long-COVID cognitive, autonomic, or exercise intolerance symptoms. Drug Pricing Policy: The Trump administration added nine mid-size drugmakers to the Most Favored Nation program, alongside $19.6B in U.S. manufacturing commitments and an expanded active pharmaceutical ingredients reserve. Vaccine Pipeline: GSK advanced its dual-antigen mRNA seasonal flu vaccine into a first-of-its-kind Phase 3 trial after stronger immune responses in Phase 2. Rare Disease Data Access: Two Irish health tech startups are merging to help rare disease patients keep one continuous health and research record instead of losing data across providers and studies. Cancer Care: Enhertu plus Perjeta won EU approval as a new frontline option for unresectable or metastatic HER2-positive breast cancer.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
